Latest Revenue News

Lode Resources has reported a statutory profit of A$456,296 after establishing an 8.2Moz silver-equivalent resource at its Montezuma project in Tasmania. The explorer is now moving from discovery toward scoping studies, but remains reliant on further drilling, metallurgy and funding to demonstrate an economic development case.

Quantum Graphite has moved Uley 2 into front-end engineering and design, renewed key mining leases and formalised its downstream structure with Sunlands Pure Group. But the company ended FY2026 with just $210,710 in cash, $10.50 million in borrowings and an auditor-documented material uncertainty over its ability to continue as a going concern.

Koonenberry Gold posted a sharply wider FY2026 loss after impairing its namesake project, while exploration spending rose and Enmore drilling extended a gold system to depth. The company has since raised $3.78 million from a placement, but remains dependent on equity funding.

Radiopharm Theranostics reported a A$56.3 million comprehensive loss for fiscal 2026, with operating cash outflows rising to A$52.8 million and cash falling to A$4.1 million. The company says further funding is required, while auditors flag a material uncertainty over its ability to continue as a going concern.

Decidr AI Industries delivered 99% revenue growth and a A$13.6 million annualised exit rate in FY26, but the company’s A$32.4 million loss and auditor-highlighted going concern uncertainty put funding at the centre of its next chapter. Management is targeting A$5 million in annualised savings while seeking to convert early AI deployments into recurring revenue.

Infotrust has completed a sweeping reshaping of its business, exiting Cloud and Communications, repaying $27 million in bank debt and acquiring Canberra cyber specialist Catalyst Cyber. The balance-sheet reset leaves the ASX-listed group targeting more than $6 million in FY27 underlying EBITDA, but its continuing business remains loss-making and execution risks are plainly visible.

Merino & Co cut its FY2026 loss by 20% as China revenue more than doubled, but group revenue declined and cash reserves fell sharply. The auditor highlighted a material uncertainty over the company’s ability to continue as a going concern.

SOCO Corporation Ltd (ASX:SOC) reported a $6.35 million FY26 statutory loss after writing down its Axsym business, even as second-half revenue, margins and cash flow improved. The company enters FY27 with $9.5 million of contracted project value carried forward and a further $4 million secured since year-end.

Estrella Resources has delivered a 27,371-tonne manganese stockpile and a maiden 621-million-tonne limestone resource in Timor-Leste, but the operational progress came alongside a $23.98 million FY2026 loss and a $21.13 million impairment of Western Australian assets. The next test is whether the manganese stockpile can become cash and whether Werumata can move beyond an Inferred resource.

archTIS delivered a sharp step-up in revenue and recurring income after acquiring Spirion, but the stronger top line came with a $16 million loss and a formal warning over its ability to fund operations. The cybersecurity company now has until late October to extend or refinance a key lending facility.

Everlast Minerals has completed its first export shipment from Bangladesh, but the 109-tonne cargo remains a pilot-scale milestone rather than proof of commercial production. The ASX-listed company ended FY26 with $3.32 million in cash, a $3.03 million loss and commissioning still incomplete at its expanded Gaibandha operation.

Clarity Pharmaceuticals is approaching pivotal Phase III readouts for its prostate cancer imaging agent, backed by AUD178.3 million in liquid assets. The radiopharmaceutical developer remains deeply loss-making, but expanded manufacturing capacity and early clinical signals are pulling its commercial ambitions into sharper focus.